ACADIA Pharmaceuticals Inc. (ACAD)
USD 15.4
(-4.47%)
USD 15.4
(-4.47%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 748.95 Million USD | 27.41% |
| 2022 | 587.81 Million USD | -16.04% |
| 2021 | 700.12 Million USD | -10.54% |
| 2020 | 782.61 Million USD | -0.07% |
| 2019 | 783.18 Million USD | 44.98% |
| 2018 | 540.2 Million USD | 40.49% |
| 2017 | 384.5 Million USD | -31.48% |
| 2016 | 561.15 Million USD | 152.89% |
| 2015 | 221.89 Million USD | -31.82% |
| 2014 | 325.45 Million USD | 72.09% |
| 2013 | 189.11 Million USD | 74.16% |
| 2012 | 108.59 Million USD | 238.14% |
| 2011 | 32.11 Million USD | -16.36% |
| 2010 | 38.39 Million USD | -22.72% |
| 2009 | 49.68 Million USD | -23.19% |
| 2008 | 64.67 Million USD | -51.94% |
| 2007 | 134.58 Million USD | 50.3% |
| 2006 | 89.54 Million USD | 43.26% |
| 2005 | 62.5 Million USD | 54.85% |
| 2004 | 40.36 Million USD | 27.36% |
| 2003 | 31.69 Million USD | 97.79% |
| 2002 | 16.02 Million USD | -27.03% |
| 2001 | 21.95 Million USD | -35.63% |
| 2000 | 34.11 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 914.09 Million USD | 6.9% |
| 2024 Q1 | 855.1 Million USD | 14.17% |
| 2023 Q1 | 655.3 Million USD | 11.48% |
| 2023 Q4 | 748.95 Million USD | 18.4% |
| 2023 Q3 | 632.54 Million USD | -1.59% |
| 2023 FY | 748.95 Million USD | 27.41% |
| 2023 Q2 | 642.76 Million USD | -1.91% |
| 2022 Q2 | 612.76 Million USD | -1.84% |
| 2022 Q1 | 624.25 Million USD | -10.84% |
| 2022 FY | 587.81 Million USD | -16.04% |
| 2022 Q4 | 587.81 Million USD | -2.44% |
| 2022 Q3 | 602.49 Million USD | -1.68% |
| 2021 Q4 | 700.12 Million USD | -2.45% |
| 2021 Q1 | 755.17 Million USD | -3.51% |
| 2021 FY | 700.12 Million USD | -10.54% |
| 2021 Q2 | 724.42 Million USD | -4.07% |
| 2021 Q3 | 717.67 Million USD | -0.93% |
| 2020 Q4 | 782.61 Million USD | -1.64% |
| 2020 FY | 782.61 Million USD | -0.07% |
| 2020 Q1 | 747.45 Million USD | -4.56% |
| 2020 Q2 | 759.64 Million USD | 1.63% |
| 2020 Q3 | 795.66 Million USD | 4.74% |
| 2019 Q4 | 783.18 Million USD | 2.3% |
| 2019 Q2 | 460.88 Million USD | -8.03% |
| 2019 FY | 783.18 Million USD | 44.98% |
| 2019 Q3 | 765.58 Million USD | 66.11% |
| 2019 Q1 | 501.1 Million USD | -7.24% |
| 2018 FY | 540.2 Million USD | 40.49% |
| 2018 Q1 | 351.04 Million USD | -8.7% |
| 2018 Q2 | 314.96 Million USD | -10.28% |
| 2018 Q3 | 266.45 Million USD | -15.4% |
| 2018 Q4 | 540.2 Million USD | 102.74% |
| 2017 Q1 | 503.01 Million USD | -10.36% |
| 2017 Q2 | 456.31 Million USD | -9.28% |
| 2017 Q4 | 384.5 Million USD | -7.06% |
| 2017 FY | 384.5 Million USD | -31.48% |
| 2017 Q3 | 413.71 Million USD | -9.34% |
| 2016 Q3 | 617.38 Million USD | 40.94% |
| 2016 Q4 | 561.15 Million USD | -9.11% |
| 2016 Q2 | 438.03 Million USD | -6.12% |
| 2016 Q1 | 466.59 Million USD | 110.27% |
| 2016 FY | 561.15 Million USD | 152.89% |
| 2015 Q2 | 275.53 Million USD | -8.75% |
| 2015 Q3 | 245.32 Million USD | -10.97% |
| 2015 Q1 | 301.96 Million USD | -7.22% |
| 2015 Q4 | 221.89 Million USD | -9.55% |
| 2015 FY | 221.89 Million USD | -31.82% |
| 2014 Q3 | 341.76 Million USD | -4.92% |
| 2014 Q2 | 359.46 Million USD | -3.76% |
| 2014 Q4 | 325.45 Million USD | -4.77% |
| 2014 Q1 | 373.5 Million USD | 97.5% |
| 2014 FY | 325.45 Million USD | 72.09% |
| 2013 FY | 189.11 Million USD | 74.16% |
| 2013 Q1 | 103.01 Million USD | -5.13% |
| 2013 Q4 | 189.11 Million USD | -5.1% |
| 2013 Q3 | 199.28 Million USD | -3.68% |
| 2013 Q2 | 206.9 Million USD | 100.85% |
| 2012 FY | 108.59 Million USD | 238.14% |
| 2012 Q4 | 108.59 Million USD | 357.22% |
| 2012 Q3 | 23.75 Million USD | 8.58% |
| 2012 Q2 | 21.87 Million USD | -17.52% |
| 2012 Q1 | 26.51 Million USD | -17.42% |
| 2011 FY | 32.11 Million USD | -16.36% |
| 2011 Q4 | 32.11 Million USD | -13.26% |
| 2011 Q1 | 46.88 Million USD | 22.12% |
| 2011 Q2 | 41.3 Million USD | -11.9% |
| 2011 Q3 | 37.02 Million USD | -10.38% |
| 2010 Q3 | 35.75 Million USD | -8.72% |
| 2010 Q2 | 39.16 Million USD | -9.49% |
| 2010 FY | 38.39 Million USD | -22.72% |
| 2010 Q4 | 38.39 Million USD | 7.4% |
| 2010 Q1 | 43.27 Million USD | -12.9% |
| 2009 Q3 | 58.47 Million USD | -16.54% |
| 2009 Q2 | 70.06 Million USD | 39.09% |
| 2009 FY | 49.68 Million USD | -23.19% |
| 2009 Q1 | 50.37 Million USD | -22.12% |
| 2009 Q4 | 49.68 Million USD | -15.04% |
| 2008 Q3 | 78.2 Million USD | -18.61% |
| 2008 Q4 | 64.67 Million USD | -17.3% |
| 2008 FY | 64.67 Million USD | -51.94% |
| 2008 Q1 | 113.32 Million USD | -15.8% |
| 2008 Q2 | 96.08 Million USD | -15.22% |
| 2007 Q2 | 160.22 Million USD | 111.52% |
| 2007 Q4 | 134.58 Million USD | -9.28% |
| 2007 Q3 | 148.34 Million USD | -7.41% |
| 2007 Q1 | 75.74 Million USD | -15.41% |
| 2007 FY | 134.58 Million USD | 50.3% |
| 2006 Q2 | 115.56 Million USD | 81.95% |
| 2006 Q3 | 100.91 Million USD | -12.68% |
| 2006 Q4 | 89.54 Million USD | -11.27% |
| 2006 FY | 89.54 Million USD | 43.26% |
| 2006 Q1 | 63.51 Million USD | 1.62% |
| 2005 Q4 | 62.5 Million USD | -11.05% |
| 2005 FY | 62.5 Million USD | 54.85% |
| 2005 Q1 | 45.92 Million USD | 13.77% |
| 2005 Q2 | 73.63 Million USD | 60.33% |
| 2005 Q3 | 70.27 Million USD | -4.56% |
| 2004 Q3 | 47.74 Million USD | -10.42% |
| 2004 Q4 | 40.36 Million USD | -15.47% |
| 2004 Q1 | 27.41 Million USD | -13.49% |
| 2004 FY | 40.36 Million USD | 27.36% |
| 2004 Q2 | 53.3 Million USD | 94.42% |
| 2003 Q4 | 31.69 Million USD | 0.0% |
| 2003 FY | 31.69 Million USD | 97.79% |
| 2002 FY | 16.02 Million USD | -27.03% |
| 2001 FY | 21.95 Million USD | -35.63% |
| 2000 FY | 34.11 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| AbCellera Biologics Inc. | 1.48 Billion USD | 49.67% |
| Alkermes plc | 2.13 Billion USD | 64.94% |
| Agenus Inc. | 313.91 Million USD | -138.587% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 80.444% |
| Aptorum Group Limited | 20.64 Million USD | -3528.647% |
| Ardelyx, Inc. | 297.57 Million USD | -151.683% |
| Arrowhead Pharmaceuticals, Inc. | 765.55 Million USD | 2.168% |
| Bicycle Therapeutics plc | 595.34 Million USD | -25.802% |
| BioXcel Therapeutics, Inc. | 73.7 Million USD | -916.195% |
| ChromaDex Corporation | 54.96 Million USD | -1262.63% |
| Chimerix, Inc. | 212.77 Million USD | -251.996% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -2549.072% |
| Caribou Biosciences, Inc. | 440.96 Million USD | -69.844% |
| CRISPR Therapeutics AG | 2.22 Billion USD | 66.408% |
| Precision BioSciences, Inc. | 159.78 Million USD | -368.739% |
| Dyadic International, Inc. | 8.21 Million USD | -9012.234% |
| Eton Pharmaceuticals, Inc. | 31.74 Million USD | -2259.66% |
| Fortress Biotech, Inc. | 167.52 Million USD | -347.069% |
| Lantern Pharma Inc. | 43.64 Million USD | -1615.915% |
| HOOKIPA Pharma Inc. | 161.33 Million USD | -364.218% |
| Inhibikase Therapeutics, Inc. | 14.5 Million USD | -5062.847% |
| Incyte Corporation | 6.78 Billion USD | 88.957% |
| IO Biotech, Inc. | 150.71 Million USD | -396.925% |
| Jaguar Health, Inc. | 50.76 Million USD | -1375.397% |
| Novavax, Inc. | 1.85 Billion USD | 59.632% |
| Janux Therapeutics, Inc. | 380.4 Million USD | -96.883% |
| Opthea Limited | 188.79 Million USD | -296.711% |
| Ligand Pharmaceuticals Incorporated | 833.06 Million USD | 10.096% |
| ContextLogic Inc. | 423 Million USD | -77.058% |
| MiMedx Group, Inc. | 239.04 Million USD | -213.309% |
| Pyxis Oncology, Inc. | 173.72 Million USD | -331.113% |
| TransCode Therapeutics, Inc. | 5.16 Million USD | -14387.414% |
| NextCure, Inc. | 129.41 Million USD | -478.711% |
| Ocuphire Pharma, Inc. | 53.94 Million USD | -1288.292% |
| Oncternal Therapeutics, Inc. | 36.72 Million USD | -1939.141% |
| Outlook Therapeutics, Inc. | 32.3 Million USD | -2218.677% |
| Vaxcyte, Inc. | 1.4 Billion USD | 46.804% |
| PDS Biotechnology Corporation | 59.39 Million USD | -1161.079% |
| Madrigal Pharmaceuticals, Inc. | 640.54 Million USD | -16.924% |
| Pharming Group N.V. | 462.85 Million USD | -61.813% |
| Pieris Pharmaceuticals, Inc. | 38.68 Million USD | -1836.287% |
| Avidity Biosciences, Inc. | 628.55 Million USD | -19.155% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | -3857.772% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | -3857.772% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | -353.034% |
| Sol-Gel Technologies Ltd. | 45.28 Million USD | -1553.799% |
| Acelyrin, Inc. | 742.69 Million USD | -0.844% |
| Salarius Pharmaceuticals, Inc. | 6.58 Million USD | -11271.037% |
| SELLAS Life Sciences Group, Inc. | 6.4 Million USD | -11596.955% |
| Summit Therapeutics Inc. | 202.94 Million USD | -269.037% |
| Sensei Biotherapeutics, Inc. | 74.37 Million USD | -907.013% |
| Senti Biosciences, Inc. | 119.48 Million USD | -526.825% |
| Stoke Therapeutics, Inc. | 228.34 Million USD | -227.997% |
| Syros Pharmaceuticals, Inc. | 168.17 Million USD | -345.346% |
| Alaunos Therapeutics, Inc. | 8.26 Million USD | -8963.972% |
| Telomir Pharmaceuticals, Inc. Common Stock | 4.77 Million USD | -15588.99% |
| Entrada Therapeutics, Inc. | 469.19 Million USD | -59.627% |
| VistaGen Therapeutics, Inc. | 123.65 Million USD | -505.692% |
| Wave Life Sciences Ltd. | 274.94 Million USD | -172.398% |
| Sorrento Therapeutics, Inc. | 472.84 Million USD | -58.395% |
| TRACON Pharmaceuticals, Inc. | 10.1 Million USD | -7311.737% |
| Barinthus Biotherapeutics plc | 214.5 Million USD | -249.154% |
| Psyence Biomedical Ltd. | 1.13 Million USD | -66052.899% |
| Phathom Pharmaceuticals, Inc. | 413.84 Million USD | -80.976% |
| Immix Biopharma, Inc. | 19.92 Million USD | -3658.846% |
| Keros Therapeutics, Inc. | 370.02 Million USD | -102.407% |
| MEI Pharma, Inc. | 41.37 Million USD | -1710.166% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | -2211.165% |
| Xeris Biopharma Holdings, Inc. | 340.79 Million USD | -119.765% |
| Rigel Pharmaceuticals, Inc. | 117.22 Million USD | -538.905% |
| Fortress Biotech, Inc. | 167.52 Million USD | -347.069% |
| Precigen, Inc. | 151.04 Million USD | -395.856% |
| Clearside Biomedical, Inc. | 34.01 Million USD | -2101.646% |
| AlloVir, Inc. | 190.79 Million USD | -292.543% |
| C4 Therapeutics, Inc. | 376.45 Million USD | -98.952% |
| Fate Therapeutics, Inc. | 506.21 Million USD | -47.952% |
| ImmuCell Corporation | 43.8 Million USD | -1609.629% |
| IDEAYA Biosciences, Inc. | 649.31 Million USD | -15.345% |
| Onconetix, Inc. | 88.82 Million USD | -743.215% |
| PureTech Health plc | 693.97 Million USD | -7.923% |
| VYNE Therapeutics Inc. | 97.68 Million USD | -666.705% |
| Elevation Oncology, Inc. | 89.09 Million USD | -740.664% |
| Kintara Therapeutics, Inc. | 6.2 Million USD | -11976.04% |
| Seer, Inc. | 436.26 Million USD | -71.673% |
| Verrica Pharmaceuticals Inc. | 81.59 Million USD | -817.872% |
| Innoviva, Inc. | 1.24 Billion USD | 39.771% |
| Aadi Bioscience, Inc. | 132.42 Million USD | -465.578% |
| ESSA Pharma Inc. | 149.12 Million USD | -402.243% |
| GlycoMimetics, Inc. | 45.31 Million USD | -1552.723% |
| GT Biopharma, Inc. | 14.1 Million USD | -5208.356% |
| Inhibrx Biosciences, Inc. | 307.89 Million USD | -143.252% |
| Akebia Therapeutics, Inc. | 241.7 Million USD | -209.866% |
| Catalyst Pharmaceuticals, Inc. | 471.9 Million USD | -58.708% |
| Longboard Pharmaceuticals, Inc. | 50.69 Million USD | -1377.318% |
| Orchestra BioMed Holdings, Inc. | 95.21 Million USD | -686.619% |
| Alzamend Neuro, Inc. | 631.58 Thousand USD | -118483.0% |
| Rocket Pharmaceuticals, Inc. | 566.34 Million USD | -32.245% |
| Aptose Biosciences Inc. | 12.92 Million USD | -5695.732% |
| ZyVersa Therapeutics, Inc. | 22.11 Million USD | -3286.752% |
| Soligenix, Inc. | 9.79 Million USD | -7544.494% |
| Century Therapeutics, Inc. | 360.69 Million USD | -107.645% |
| Kura Oncology, Inc. | 448.93 Million USD | -66.829% |
| TScan Therapeutics, Inc. | 272.14 Million USD | -175.201% |
| Intensity Therapeutics, Inc. | 17.29 Million USD | -4230.477% |
| Ocean Biomedical, Inc. | 110.91 Million USD | -575.275% |
| CytomX Therapeutics, Inc. | 205.15 Million USD | -265.075% |
| Autolus Therapeutics plc | 375.38 Million USD | -99.519% |
| Mineralys Therapeutics, Inc. | 251.63 Million USD | -197.635% |
| EyePoint Pharmaceuticals, Inc. | 355.18 Million USD | -110.864% |
| Eterna Therapeutics Inc. | 49.13 Million USD | -1424.375% |
| Adaptive Biotechnologies Corporation | 661.13 Million USD | -13.284% |
| GRI Bio, Inc. | 2.95 Million USD | -25236.806% |
| Xenetic Biosciences, Inc. | 10.6 Million USD | -6962.141% |
| Tenaya Therapeutics, Inc. | 170.51 Million USD | -339.232% |
| IGM Biosciences, Inc. | 423.41 Million USD | -76.886% |
| INmune Bio, Inc. | 57 Million USD | -1213.935% |
| Heron Therapeutics, Inc. | 222.5 Million USD | -236.6% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | -792.238% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | -2767.711% |
| Entero Therapeutics, Inc. | 6.88 Million USD | -10780.935% |
| Milestone Pharmaceuticals Inc. | 75.22 Million USD | -895.608% |
| X4 Pharmaceuticals, Inc. | 147.25 Million USD | -408.601% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | -352.53% |
| Coherus BioSciences, Inc. | 629.6 Million USD | -18.957% |
| Verastem, Inc. | 149.71 Million USD | -400.244% |
| Abeona Therapeutics Inc. | 64 Million USD | -1070.207% |
| Pliant Therapeutics, Inc. | 512.15 Million USD | -46.236% |
| Tonix Pharmaceuticals Holding Corp. | 154.45 Million USD | -384.896% |
| Histogen Inc. | 19.07 Million USD | -3826.787% |
| Aprea Therapeutics, Inc. | 22.65 Million USD | -3206.624% |
| Surrozen, Inc. | 46.08 Million USD | -1525.339% |
| Organovo Holdings, Inc. | 6.34 Million USD | -11696.44% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -17282.735% |
| Ovid Therapeutics Inc. | 144.02 Million USD | -420.012% |
| Panbela Therapeutics, Inc. | 11.8 Million USD | -6246.009% |
| CASI Pharmaceuticals, Inc. | 75.26 Million USD | -895.052% |
| Cadrenal Therapeutics, Inc. Common Stock | 8.51 Million USD | -8691.337% |
| Centessa Pharmaceuticals plc | 362.96 Million USD | -106.342% |
| Hepion Pharmaceuticals, Inc. | 18.09 Million USD | -4039.16% |
| Arcturus Therapeutics Holdings Inc. | 429.4 Million USD | -74.418% |
| BioRestorative Therapies, Inc. | 12.61 Million USD | -5838.571% |
| Apollomics, Inc. | 55.38 Million USD | -1252.223% |
| Amarin Corporation plc | 831.68 Million USD | 9.947% |
| Mesoblast Limited | 669.15 Million USD | -11.926% |
| Turnstone Biologics Corp. | 112.81 Million USD | -563.88% |
| Kymera Therapeutics, Inc. | 575.75 Million USD | -30.082% |
| Synaptogenix, Inc. | 31.11 Million USD | -2307.161% |
| Tiziana Life Sciences Ltd | 12.18 Million USD | -6047.045% |
| Aurinia Pharmaceuticals Inc. | 548.06 Million USD | -36.655% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -12654.133% |
| Monopar Therapeutics Inc. | 7.34 Million USD | -10096.593% |
| Exelixis, Inc. | 2.94 Billion USD | 74.546% |
| Better Therapeutics, Inc. | 22.94 Million USD | -3164.421% |
| Nurix Therapeutics, Inc. | 364.53 Million USD | -105.453% |
| Apellis Pharmaceuticals, Inc. | 788.73 Million USD | 5.043% |
| NLS Pharmaceutics AG | 1.84 Million USD | -40457.748% |
| Dermata Therapeutics, Inc. | 7.97 Million USD | -9287.02% |
| Aridis Pharmaceuticals, Inc. | 14.69 Million USD | -4996.672% |
| Gritstone bio, Inc. | 177.76 Million USD | -321.309% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | -685.234% |
| TNF Pharmaceuticals, Inc. | 17.86 Million USD | -4092.95% |
| Avid Bioservices, Inc. | 336.55 Million USD | -122.535% |
| Insmed Incorporated | 1.32 Billion USD | 43.681% |
| Virpax Pharmaceuticals, Inc. | 9.62 Million USD | -7678.658% |
| MediWound Ltd. | 66.45 Million USD | -1026.944% |
| OmniAb, Inc. | 401.98 Million USD | -86.314% |
| Alector, Inc. | 621.82 Million USD | -20.444% |
| Seres Therapeutics, Inc. | 358.6 Million USD | -108.856% |
| Checkpoint Therapeutics, Inc. | 5.37 Million USD | -13826.292% |
| Viracta Therapeutics, Inc. | 56.69 Million USD | -1221.096% |
| Zai Lab Limited | 1.03 Billion USD | 27.728% |
| Revance Therapeutics, Inc. | 478.45 Million USD | -56.537% |
| Aura Biosciences, Inc. | 255.07 Million USD | -193.622% |
| Lyell Immunopharma, Inc. | 750.02 Million USD | 0.143% |
| Immunic, Inc. | 54.29 Million USD | -1279.318% |
| Tarsus Pharmaceuticals, Inc. | 266.22 Million USD | -181.326% |
| Veracyte, Inc. | 1.13 Billion USD | 34.176% |
| InMed Pharmaceuticals Inc. | 11.82 Million USD | -6234.854% |
| FibroGen, Inc. | 423.52 Million USD | -76.837% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -21219.556% |
| Adial Pharmaceuticals, Inc. | 4.73 Million USD | -15712.085% |
| Sonnet BioTherapeutics Holdings, Inc. | 5.42 Million USD | -13694.254% |
| Jazz Pharmaceuticals plc | 11.39 Billion USD | 93.426% |
| Cyclacel Pharmaceuticals, Inc. | 8.8 Million USD | -8406.031% |
| Amylyx Pharmaceuticals, Inc. | 517.45 Million USD | -44.739% |
| TG Therapeutics, Inc. | 329.58 Million USD | -127.241% |
| Galecto, Inc. | 38.22 Million USD | -1859.233% |
| Calithera Biosciences, Inc. | 28.67 Million USD | -2511.787% |
| Fortrea Holdings Inc. | 4.35 Billion USD | 82.811% |
| KalVista Pharmaceuticals, Inc. | 235.4 Million USD | -218.158% |
| Aptevo Therapeutics Inc. | 24.84 Million USD | -2914.878% |
| XBiotech Inc. | 227.24 Million USD | -229.584% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | -685.234% |
| Lyra Therapeutics, Inc. | 142.6 Million USD | -425.215% |
| Foghorn Therapeutics Inc. | 285.91 Million USD | -161.95% |
| Y-mAbs Therapeutics, Inc. | 127.86 Million USD | -485.721% |
| Theravance Biopharma, Inc. | 381.99 Million USD | -96.062% |
| Ultragenyx Pharmaceutical Inc. | 1.49 Billion USD | 49.769% |
| Metagenomi, Inc. Common Stock | 364.84 Million USD | -105.282% |
| Vaxxinity, Inc. | 44.35 Million USD | -1588.625% |
| BioCryst Pharmaceuticals, Inc. | 516.96 Million USD | -44.877% |
| Gain Therapeutics, Inc. | 18.6 Million USD | -3924.626% |
| Cartesian Therapeutics, Inc. | 305.05 Million USD | -145.519% |
| NexImmune, Inc. | 8.59 Million USD | -8614.923% |
| Creative Medical Technology Holdings, Inc. | 10.71 Million USD | -6889.666% |
| Marker Therapeutics, Inc. | 17.12 Million USD | -4272.855% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 97.736% |
| Chemomab Therapeutics Ltd. | 22.15 Million USD | -3281.119% |
| Scopus BioPharma Inc. | 392.26 Thousand USD | -190831.131% |
| RAPT Therapeutics, Inc. | 173.32 Million USD | -332.101% |
| Ainos, Inc. | 31.84 Million USD | -2252.115% |
| Pluri Inc. | 39.52 Million USD | -1794.796% |
| Prothena Corporation plc | 696.38 Million USD | -7.55% |
| Adaptimmune Therapeutics plc | 282.61 Million USD | -165.008% |
| Celularity Inc. | 143.88 Million USD | -420.51% |
| Rallybio Corporation | 115.62 Million USD | -547.774% |
| Cue Biopharma, Inc. | 61.53 Million USD | -1117.221% |
| MeiraGTx Holdings plc | 458.16 Million USD | -63.468% |
| Omeros Corporation | 378.26 Million USD | -97.996% |
| Humacyte, Inc. | 128.22 Million USD | -484.104% |
| Immunocore Holdings plc | 597 Million USD | -25.453% |
| Cocrystal Pharma, Inc. | 31.25 Million USD | -2295.969% |
| Cidara Therapeutics, Inc. | 68.53 Million USD | -992.888% |
| Blueprint Medicines Corporation | 1.04 Billion USD | 28.62% |
| CalciMedica, Inc. | 12.18 Million USD | -6046.541% |
| Cabaletta Bio, Inc. | 253.65 Million USD | -195.271% |
| Marinus Pharmaceuticals, Inc. | 170.9 Million USD | -338.222% |
| Scholar Rock Holding Corporation | 311.03 Million USD | -140.795% |
| Sana Biotechnology, Inc. | 565.29 Million USD | -32.488% |
| Pulmatrix, Inc. | 33.95 Million USD | -2105.536% |
| Elicio Therapeutics, Inc. | 27.14 Million USD | -2658.992% |
| Vigil Neuroscience, Inc. | 140.85 Million USD | -431.71% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | 42.431% |
| Adlai Nortye Ltd. American Depositary Shares | 130.18 Million USD | -475.284% |
| Cytokinetics, Incorporated | 824.31 Million USD | 9.142% |
| Eloxx Pharmaceuticals, Inc. | 21.12 Million USD | -3445.69% |
| Nutriband Inc. | 7.51 Million USD | -9863.292% |
| Protara Therapeutics, Inc. | 78.95 Million USD | -848.598% |
| Vor Biopharma Inc. | 209.82 Million USD | -256.938% |
| Roivant Sciences Ltd. | 7.22 Billion USD | 89.63% |
| Evogene Ltd. | 51.1 Million USD | -1365.639% |
| ProKidney Corp. | 420.55 Million USD | -78.089% |
| Applied Therapeutics, Inc. | 54.83 Million USD | -1265.886% |
| Hoth Therapeutics, Inc. | 9.52 Million USD | -7766.955% |
| BridgeBio Pharma, Inc. | 546.38 Million USD | -37.076% |
| CorMedix Inc. | 82.05 Million USD | -812.694% |
| BioLineRx Ltd. | 63.92 Million USD | -1071.617% |
| Tango Therapeutics, Inc. | 402.56 Million USD | -86.045% |
| Galectin Therapeutics Inc. | 28.2 Million USD | -2555.872% |
| Atai Life Sciences N.V. | 293.47 Million USD | -155.2% |
| Renovaro Biosciences Inc. | 163.12 Million USD | -359.118% |
| Aerovate Therapeutics, Inc. | 127.41 Million USD | -487.795% |
| Zentalis Pharmaceuticals, Inc. | 562.02 Million USD | -33.26% |
| Sagimet Biosciences Inc. | 96.71 Million USD | -674.363% |
| MediciNova, Inc. | 66.26 Million USD | -1030.159% |
| Praxis Precision Medicines, Inc. | 87.94 Million USD | -751.59% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -16683.835% |
| GeoVax Labs, Inc. | 9.28 Million USD | -7967.848% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | -27.322% |
| Biomea Fusion, Inc. | 199.92 Million USD | -274.615% |
| PTC Therapeutics, Inc. | 1.9 Billion USD | 60.647% |
| Mereo BioPharma Group plc | 66.49 Million USD | -1026.267% |
| Cullinan Oncology, Inc. | 485.09 Million USD | -54.393% |
| Syndax Pharmaceuticals, Inc. | 612.88 Million USD | -22.203% |
| Absci Corporation | 234.48 Million USD | -219.411% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -10138.633% |
| 4D Molecular Therapeutics, Inc. | 339.89 Million USD | -120.352% |
| Dyne Therapeutics, Inc. | 165.08 Million USD | -353.687% |
| Kiniksa Pharmaceuticals, Ltd. | 526.32 Million USD | -42.3% |
| Ventyx Biosciences, Inc. | 277.69 Million USD | -169.706% |
| Allakos Inc. | 243.61 Million USD | -207.441% |
| Imunon, Inc. | 21.91 Million USD | -3317.071% |
| Fulcrum Therapeutics, Inc. | 257.69 Million USD | -190.638% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | -20.505% |
| BioAtla, Inc. | 119.65 Million USD | -525.914% |
| NLS Pharmaceutics AG | 1.84 Million USD | -40457.748% |
| Bio-Path Holdings, Inc. | 3.22 Million USD | -23159.503% |
| Allogene Therapeutics, Inc. | 642.83 Million USD | -16.508% |
| Larimar Therapeutics, Inc. | 95.93 Million USD | -680.691% |
| XOMA Corporation | 234.3 Million USD | -219.655% |
| Kezar Life Sciences, Inc. | 221.23 Million USD | -238.534% |
| Cara Therapeutics, Inc. | 125.84 Million USD | -495.146% |
| aTyr Pharma, Inc. | 122.06 Million USD | -513.561% |
| Aligos Therapeutics, Inc. | 153.9 Million USD | -386.642% |
| Akero Therapeutics, Inc. | 580.27 Million USD | -29.07% |
| Viridian Therapeutics, Inc. | 490.42 Million USD | -52.716% |
| Eliem Therapeutics, Inc. | 110.46 Million USD | -577.978% |
| EyeGate Pharmaceuticals, Inc. | 15.15 Million USD | -4841.139% |
| Akari Therapeutics, Plc | 4.35 Million USD | -17097.612% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | -4295.97% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | 56.789% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -24185.324% |
| UroGen Pharma Ltd. | 178.31 Million USD | -320.028% |
| Sutro Biopharma, Inc. | 470.73 Million USD | -59.103% |
| ZIVO Bioscience, Inc. | 555.71 Thousand USD | -134673.4% |
| Orgenesis Inc. | 14.55 Million USD | -5046.756% |
| Entera Bio Ltd. | 11.76 Million USD | -6265.967% |
| GH Research PLC | 226.3 Million USD | -230.957% |
| Lisata Therapeutics, Inc. | 54.69 Million USD | -1269.357% |
| Reneo Pharmaceuticals, Inc. | 107.43 Million USD | -597.118% |
| Xencor, Inc. | 952.69 Million USD | 21.385% |
| 60 Degrees Pharmaceuticals, Inc. | 7.78 Million USD | -9522.02% |
| Replimune Group, Inc. | 487.72 Million USD | -53.562% |
| Coeptis Therapeutics Holdings, Inc. | 8.07 Million USD | -9179.491% |
| Vanda Pharmaceuticals Inc. | 648.44 Million USD | -15.501% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -24185.324% |
| Portage Biotech Inc. | 7.77 Million USD | -9527.921% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -16683.835% |
| Olema Pharmaceuticals, Inc. | 276.94 Million USD | -170.435% |
| OncoCyte Corporation | 74.89 Million USD | -900.048% |
| Qualigen Therapeutics, Inc. | 2.03 Million USD | -36735.448% |
| Processa Pharmaceuticals, Inc. | 5.78 Million USD | -12842.841% |
| Purple Biotech Ltd. | 44.3 Million USD | -1590.569% |
| CollPlant Biotechnologies Ltd. | 34.12 Million USD | -2094.679% |
| scPharmaceuticals Inc. | 94.47 Million USD | -692.722% |
| ProMIS Neurosciences, Inc. | 18.04 Million USD | -4050.5% |
| HilleVax, Inc. | 344.43 Million USD | -117.445% |
| NeuroSense Therapeutics Ltd. | 3.17 Million USD | -23481.738% |
| Tharimmune, Inc. | 10.94 Million USD | -6742.035% |
| Genprex, Inc. | 10.67 Million USD | -6918.88% |
| Neumora Therapeutics, Inc. Common Stock | 496.19 Million USD | -50.94% |
| Atossa Therapeutics, Inc. | 96.25 Million USD | -678.12% |
| XTL Biopharmaceuticals Ltd. | 2.42 Million USD | -30772.053% |
| Virios Therapeutics, Inc. | 4.16 Million USD | -17880.233% |
| OKYO Pharma Limited | 1.54 Million USD | -48493.622% |
| Savara Inc. | 177.56 Million USD | -321.795% |
| Curis, Inc. | 77.28 Million USD | -869.121% |
| Daré Bioscience, Inc. | 21.28 Million USD | -3419.164% |
| Carmell Therapeutics Corporation | 63.94 Million USD | -1071.181% |
| Titan Pharmaceuticals, Inc. | 8.08 Million USD | -9162.379% |
| Achieve Life Sciences, Inc. | 19.37 Million USD | -3766.378% |
| BeiGene, Ltd. | 5.8 Billion USD | 87.099% |
| Kiromic BioPharma, Inc. | 12.16 Million USD | -6054.622% |
| Revolution Medicines, Inc. Warrant | 2.08 Billion USD | 64.141% |
| Protagonist Therapeutics, Inc. | 357.95 Million USD | -109.234% |
| Erasca, Inc. | 395.29 Million USD | -89.467% |
| bluebird bio, Inc. | 619.16 Million USD | -20.963% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -17223.435% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 89.053% |
| DBV Technologies S.A. | 182.98 Million USD | -309.297% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -17223.435% |
| Moderna, Inc. | 18.42 Billion USD | 95.935% |
| Vincerx Pharma, Inc. | 18.21 Million USD | -4011.303% |
| Fresh Tracks Therapeutics, Inc. | 11.58 Million USD | -6364.319% |
| Molecular Templates, Inc. | 35.38 Million USD | -2016.711% |
| Acrivon Therapeutics, Inc. Common Stock | 138.26 Million USD | -441.682% |
| Travere Therapeutics, Inc. | 788.91 Million USD | 5.065% |
| Monte Rosa Therapeutics, Inc. | 303.75 Million USD | -146.566% |
| Spruce Biosciences, Inc. | 103.94 Million USD | -620.524% |
| Celldex Therapeutics, Inc. | 465.62 Million USD | -60.849% |
| Cogent Biosciences, Inc. | 313.43 Million USD | -138.949% |
| MacroGenics, Inc. | 306.82 Million USD | -144.103% |
| RenovoRx, Inc. | 1.46 Million USD | -50988.404% |
| Adicet Bio, Inc. | 207.29 Million USD | -261.3% |
| Prime Medicine, Inc. | 193.85 Million USD | -286.357% |
| Aditxt, Inc. | 44.57 Million USD | -1580.09% |
| Adagene Inc. | 115.72 Million USD | -547.165% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -16714.643% |
| Quantum-Si incorporated | 298.25 Million USD | -151.117% |
| Maravai LifeSciences Holdings, Inc. | 1.48 Billion USD | 49.648% |
| Acurx Pharmaceuticals, Inc. | 7.7 Million USD | -9615.191% |
| Voyager Therapeutics, Inc. | 351.28 Million USD | -113.207% |
| SciSparc Ltd. | 11.18 Million USD | -6597.872% |
| Vericel Corporation | 353.65 Million USD | -111.775% |
| Revelation Biosciences, Inc. | 12.21 Million USD | -6032.645% |
| Minerva Neurosciences, Inc. | 56.9 Million USD | -1216.253% |
| Generation Bio Co. | 374.75 Million USD | -99.851% |
| Astria Therapeutics, Inc. | 254.66 Million USD | -194.093% |
| Black Diamond Therapeutics, Inc. | 158.56 Million USD | -372.328% |
| Arcutis Biotherapeutics, Inc. | 341.36 Million USD | -119.4% |
| Invivyd, Inc. | 229.18 Million USD | -226.797% |
| Relay Therapeutics, Inc. | 843.98 Million USD | 11.259% |
| Quoin Pharmaceuticals, Ltd. | 12.16 Million USD | -6054.47% |
| Spero Therapeutics, Inc. | 182.39 Million USD | -310.634% |
| Artelo Biosciences, Inc. | 20.42 Million USD | -3567.039% |
| 2seventy bio, Inc. | 565.42 Million USD | -32.459% |
| ADMA Biologics, Inc. | 329.18 Million USD | -127.52% |
| Clene Inc. | 52.34 Million USD | -1330.916% |
| Capricor Therapeutics, Inc. | 58.73 Million USD | -1175.159% |
| Boundless Bio, Inc. Common Stock | 129.89 Million USD | -476.59% |
| GeoVax Labs, Inc. | 9.28 Million USD | -7967.848% |
| Recursion Pharmaceuticals, Inc. | 653.69 Million USD | -14.572% |
| Citius Pharmaceuticals, Inc. | 103.61 Million USD | -622.853% |
| Contineum Therapeutics, Inc. Class A Common Stock | 130.38 Million USD | -474.414% |
| Relmada Therapeutics, Inc. | 97.55 Million USD | -667.75% |
| Finch Therapeutics Group, Inc. | 70.99 Million USD | -954.912% |
| ALX Oncology Holdings Inc. | 242.55 Million USD | -208.78% |
| Vir Biotechnology, Inc. | 1.96 Billion USD | 61.79% |
| Evaxion Biotech A/S | 12.88 Million USD | -5710.987% |
| Ocular Therapeutix, Inc. | 252.06 Million USD | -197.134% |
| Verve Therapeutics, Inc. | 752.68 Million USD | 0.496% |
| Trevena, Inc. | 40.6 Million USD | -1744.492% |
| Surrozen, Inc. | 46.08 Million USD | -1525.339% |
| Tyra Biosciences, Inc. | 225.85 Million USD | -231.606% |
| Cingulate Inc. | 3.49 Million USD | -21351.231% |
| Galmed Pharmaceuticals Ltd. | 16.62 Million USD | -4403.915% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -1040.137% |
| Tenax Therapeutics, Inc. | 11.68 Million USD | -6309.755% |
| Terns Pharmaceuticals, Inc. | 268.51 Million USD | -178.923% |
| Connect Biopharma Holdings Limited | 125.89 Million USD | -494.919% |
| Clearmind Medicine Inc. | 4.32 Million USD | -17219.348% |
| Kronos Bio, Inc. | 213.27 Million USD | -251.163% |
| Bolt Biotherapeutics, Inc. | 159.78 Million USD | -368.73% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -8648.863% |
| Viking Therapeutics, Inc. | 368.49 Million USD | -103.25% |
| Statera Biopharma, Inc. | 21.16 Million USD | -3437.87% |
| ImmunityBio, Inc. | 504.45 Million USD | -48.469% |
| Korro Bio, Inc. | 221.66 Million USD | -237.88% |
| Kineta, Inc. | 10.28 Million USD | -7184.856% |
| BioVie Inc. | 25.2 Million USD | -2871.064% |
| Codexis, Inc. | 136.56 Million USD | -448.441% |
| Celularity Inc. | 143.88 Million USD | -420.51% |
| Crinetics Pharmaceuticals, Inc. | 635.35 Million USD | -17.88% |
| Celcuity Inc. | 191.21 Million USD | -291.674% |
| Virax Biolabs Group Limited | 5.48 Million USD | -13557.189% |
| Cibus, Inc. | 544.41 Million USD | -37.572% |
| Eledon Pharmaceuticals, Inc. | 125.89 Million USD | -494.91% |
| eFFECTOR Therapeutics, Inc. | 20.54 Million USD | -3545.619% |
| IN8bio, Inc. | 33.7 Million USD | -2121.828% |
| Kodiak Sciences Inc. | 479.37 Million USD | -56.237% |
| Annexon, Inc. | 297.67 Million USD | -151.603% |
| Adverum Biotechnologies, Inc. | 173.01 Million USD | -332.898% |
| Assembly Biosciences, Inc. | 137.46 Million USD | -444.818% |
| Avalo Therapeutics, Inc. | 20.99 Million USD | -3467.646% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | 74.952% |
| Eyenovia, Inc. | 28.77 Million USD | -2502.405% |
| Puma Biotechnology, Inc. | 230.52 Million USD | -224.887% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -10267.608% |
| Xilio Therapeutics, Inc. | 60.92 Million USD | -1129.288% |
| Arcellx, Inc. | 825.13 Million USD | 9.232% |
| Cardiff Oncology, Inc. | 81.63 Million USD | -817.422% |
| Enanta Pharmaceuticals, Inc. | 462.27 Million USD | -62.015% |
| Regulus Therapeutics Inc. | 30.75 Million USD | -2335.629% |
| Moolec Science SA | 24.05 Million USD | -3013.995% |
| Acumen Pharmaceuticals, Inc. | 310.12 Million USD | -141.501% |
| Geron Corporation | 394.07 Million USD | -90.054% |
| LAVA Therapeutics N.V. | 101.71 Million USD | -636.364% |
| Royalty Pharma plc | 16.38 Billion USD | 95.428% |
| Atea Pharmaceuticals, Inc. | 594.96 Million USD | -25.882% |
| Greenwich LifeSciences, Inc. | 6.99 Million USD | -10607.302% |
| TFF Pharmaceuticals, Inc. | 12.02 Million USD | -6127.125% |
| Mersana Therapeutics, Inc. | 226.06 Million USD | -231.309% |
| Humacyte, Inc. | 128.22 Million USD | -484.104% |
| Structure Therapeutics Inc. | 482.01 Million USD | -55.38% |
| 89bio, Inc. | 596.26 Million USD | -25.607% |
| PMV Pharmaceuticals, Inc. | 252.15 Million USD | -197.026% |
| Avenue Therapeutics, Inc. | 1.85 Million USD | -40384.108% |
| Genelux Corporation | 27.89 Million USD | -2585.104% |
| Trevi Therapeutics, Inc. | 89.4 Million USD | -737.73% |
| Lexicon Pharmaceuticals, Inc. | 229.42 Million USD | -226.443% |
| Notable Labs, Ltd. | 19.54 Million USD | -3732.741% |
| Liquidia Corporation | 120.43 Million USD | -521.896% |
| Mustang Bio, Inc. | 17.74 Million USD | -4121.373% |
| Immunovant, Inc. | 666.71 Million USD | -12.336% |
| Quantum-Si incorporated | 298.25 Million USD | -151.117% |
| Arbutus Biopharma Corporation | 144.4 Million USD | -418.664% |
| DiaMedica Therapeutics Inc. | 54.16 Million USD | -1282.858% |
| Vera Therapeutics, Inc. | 175.54 Million USD | -326.644% |
| Acasti Pharma Inc. | 73.3 Million USD | -921.768% |
| MiNK Therapeutics, Inc. | 4.55 Million USD | -16352.324% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | -2767.711% |
| Xenon Pharmaceuticals Inc. | 964.79 Million USD | 22.372% |
| Elevai Labs, Inc. Common Stock | 5.18 Million USD | -14330.979% |
| NeuroBo Pharmaceuticals, Inc. | 22.78 Million USD | -3187.634% |
| Tempest Therapeutics, Inc. | 51.6 Million USD | -1351.381% |
| Soleno Therapeutics, Inc. | 180.69 Million USD | -314.495% |
| PepGen Inc. | 143.05 Million USD | -423.555% |
| Moleculin Biotech, Inc. | 38.21 Million USD | -1859.746% |
| United Therapeutics Corporation | 7.16 Billion USD | 89.55% |
| Nuvectis Pharma, Inc. | 19.18 Million USD | -3803.862% |
| Solid Biosciences Inc. | 164.93 Million USD | -354.081% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -12654.133% |
| Immuneering Corporation | 102.58 Million USD | -630.087% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -17282.735% |
| Silo Pharma, Inc. | 7.74 Million USD | -9568.763% |
| Belite Bio, Inc | 94.64 Million USD | -691.357% |
| XOMA Corporation | 234.3 Million USD | -219.655% |
| ARS Pharmaceuticals, Inc. | 233.18 Million USD | -221.181% |
| Bionomics Limited | 27.64 Million USD | -2608.79% |
| Apogee Therapeutics, Inc. | 401.4 Million USD | -86.584% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | -597.43% |
| uniQure N.V. | 831.68 Million USD | 9.948% |
| Cassava Sciences, Inc. | 151.66 Million USD | -393.829% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -16714.643% |
| Poseida Therapeutics, Inc. | 273.88 Million USD | -173.456% |
| Forte Biosciences, Inc. | 38.98 Million USD | -1821.385% |
| Anebulo Pharmaceuticals, Inc. | 4.07 Million USD | -18287.799% |
| Enlivex Therapeutics Ltd. | 36.83 Million USD | -1933.494% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -10267.608% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -21219.556% |
| FibroBiologics, Inc. Common Stock | 11.82 Million USD | -6235.809% |
| Altimmune, Inc. | 210.64 Million USD | -255.562% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | 3.718% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | -597.43% |
| Compugen Ltd. | 121.33 Million USD | -517.268% |
| Peak Bio, Inc. | 2.59 Million USD | -28745.774% |
| Zevra Therapeutics, Inc. | 172.32 Million USD | -334.613% |
| Benitec Biopharma Inc. | 52.21 Million USD | -1334.507% |
| Spyre Therapeutics, Inc. | 341.85 Million USD | -119.083% |
| NKGen Biotech, Inc. Common Stock | 34.77 Million USD | -2053.843% |
| Zura Bio Limited | 100.84 Million USD | -642.695% |
| PolyPid Ltd. | 15.37 Million USD | -4772.209% |
| Aileron Therapeutics, Inc. | 119.28 Million USD | -527.866% |
| NKGen Biotech, Inc. Warrants | 34.77 Million USD | -2053.843% |
| Instil Bio, Inc. | 325.63 Million USD | -130.002% |
| argenx SE | 4.54 Billion USD | 83.512% |
| Immunome, Inc. | 148.54 Million USD | -404.212% |
| Compass Therapeutics, Inc. | 156.87 Million USD | -377.422% |
| Verona Pharma plc | 308.12 Million USD | -143.07% |
| enGene Holdings Inc. Warrants | 86.95 Million USD | -761.275% |
| Shattuck Labs, Inc. | 159.56 Million USD | -369.377% |
| CervoMed Inc. | 9.97 Million USD | -7410.197% |
| LENZ Therapeutics, Inc. | 188.45 Million USD | -297.417% |
| Plus Therapeutics, Inc. | 11.38 Million USD | -6476.712% |
| Dianthus Therapeutics, Inc. | 179.4 Million USD | -317.467% |
| Moolec Science SA | 24.05 Million USD | -3013.995% |
| Enveric Biosciences, Inc. | 6.11 Million USD | -12142.884% |
| Inovio Pharmaceuticals, Inc. | 172.94 Million USD | -333.062% |
| AnaptysBio, Inc. | 452.38 Million USD | -65.556% |
| Design Therapeutics, Inc. | 289.64 Million USD | -158.579% |
| Leap Therapeutics, Inc. | 72.82 Million USD | -928.433% |
| NeurAxis, Inc. | 509.49 Thousand USD | -146898.811% |
| Seelos Therapeutics, Inc. | 5.41 Million USD | -13723.477% |
| Lumos Pharma, Inc. | 40.63 Million USD | -1742.994% |
| Achilles Therapeutics plc | 161.45 Million USD | -363.876% |
| enGene Holdings Inc. Common Stock | 86.95 Million USD | -761.275% |
| 180 Life Sciences Corp. | 5.25 Million USD | -14140.126% |
| Opiant Pharmaceuticals, Inc. | 70.42 Million USD | -963.438% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -8648.863% |
| Nutriband Inc. | 7.51 Million USD | -9863.292% |
| ORIC Pharmaceuticals, Inc. | 254.68 Million USD | -194.07% |
| CG Oncology, Inc. Common stock | 199.3 Million USD | -275.791% |
| Fractyl Health, Inc. Common Stock | 76.21 Million USD | -882.727% |
| Rani Therapeutics Holdings, Inc. | 57.91 Million USD | -1193.176% |
| MoonLake Immunotherapeutics | 526.54 Million USD | -42.241% |
| Palisade Bio, Inc. | 14.05 Million USD | -5229.889% |
| Tourmaline Bio, Inc. | 210.29 Million USD | -256.145% |
| Beam Therapeutics Inc. | 1.45 Billion USD | 48.692% |
| Neurogene Inc. | 222.57 Million USD | -236.499% |
| Mirum Pharmaceuticals, Inc. | 646.62 Million USD | -15.826% |
| AEON Biopharma, Inc. | 6.84 Million USD | -10841.651% |
| CARGO Therapeutics, Inc. Common Stock | 453.03 Million USD | -65.319% |
| Sesen Bio, Inc. | 189.17 Million USD | -295.909% |
| Enliven Therapeutics, Inc. | 271.86 Million USD | -175.486% |
| Kiora Pharmaceuticals, Inc. | 13.71 Million USD | -5362.1% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | 4.023% |
| Taysha Gene Therapies, Inc. | 266.99 Million USD | -180.514% |
| Athira Pharma, Inc. | 160.24 Million USD | -367.382% |
| Vaccinex, Inc. | 3.63 Million USD | -20526.714% |
| HCW Biologics Inc. | 28.51 Million USD | -2526.657% |
| XOMA Corporation | 234.3 Million USD | -219.655% |
| Nektar Therapeutics | 398.03 Million USD | -88.164% |
| Arvinas, Inc. | 1.3 Billion USD | 42.591% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | -4295.97% |
| Merus N.V. | 458.49 Million USD | -63.351% |
| Omega Therapeutics, Inc. | 204.36 Million USD | -266.478% |
| Quince Therapeutics, Inc. | 180.2 Million USD | -315.616% |
| Rezolute, Inc. | 132.73 Million USD | -464.241% |
| Clene Inc. | 52.34 Million USD | -1330.916% |
| Indaptus Therapeutics, Inc. | 14.92 Million USD | -4918.508% |
| BeyondSpring Inc. | 24.8 Million USD | -2919.01% |
| Synlogic, Inc. | 75.55 Million USD | -891.338% |
| Allarity Therapeutics, Inc. | 11.86 Million USD | -6213.91% |
| Phio Pharmaceuticals Corp. | 9.36 Million USD | -7898.249% |
| Peak Bio, Inc. | 2.59 Million USD | -28745.774% |
| Werewolf Therapeutics, Inc. | 174.83 Million USD | -328.384% |
| Krystal Biotech, Inc. | 818.35 Million USD | 8.48% |
| Karyopharm Therapeutics Inc. | 240.43 Million USD | -211.497% |
| SpringWorks Therapeutics, Inc. | 725.78 Million USD | -3.192% |
| Lipella Pharmaceuticals Inc. | 3.57 Million USD | -20837.086% |
| MannKind Corporation | 475.19 Million USD | -57.609% |
| Ikena Oncology, Inc. | 192.09 Million USD | -289.894% |
| Cyclerion Therapeutics, Inc. | 13.37 Million USD | -5500.09% |
| Gyre Therapeutics, Inc. | 116.53 Million USD | -542.666% |
| Gossamer Bio, Inc. | 311.91 Million USD | -140.115% |
| CohBar, Inc. | 16.36 Million USD | -4476.385% |
| Cognition Therapeutics, Inc. | 35.16 Million USD | -2029.955% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -10138.633% |
| Legend Biotech Corporation | 1.84 Billion USD | 59.485% |
| Mural Oncology plc | 301.74 Million USD | -148.208% |
| Biora Therapeutics, Inc. | 31.21 Million USD | -2299.346% |
| PaxMedica, Inc. Common Stock | 5.68 Million USD | -13084.905% |
| Disc Medicine, Inc. | 367.99 Million USD | -103.523% |
| Champions Oncology, Inc. | 26.13 Million USD | -2766.049% |
| REGENXBIO Inc. | 573.97 Million USD | -30.487% |
| Ensysce Biosciences, Inc. | 2.7 Million USD | -27556.296% |
| Anavex Life Sciences Corp. | 154.38 Million USD | -385.119% |
| Cellectar Biosciences, Inc. | 12.07 Million USD | -6102.236% |
| Edgewise Therapeutics, Inc. | 340.03 Million USD | -120.259% |
| Vaxart, Inc. | 91.83 Million USD | -715.59% |
| PharmaCyte Biotech, Inc. | 59.9 Million USD | -1150.263% |
| Aldeyra Therapeutics, Inc. | 148.32 Million USD | -404.936% |
| Cellectis S.A. | 334.27 Million USD | -124.057% |
| Longeveron Inc. | 12.17 Million USD | -6050.074% |
| Repare Therapeutics Inc. | 253.9 Million USD | -194.98% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | 77.058% |
| Inozyme Pharma, Inc. | 200.84 Million USD | -272.899% |
| Revolution Medicines, Inc. | 2.08 Billion USD | 64.141% |
| Nymox Pharmaceutical Corporation | 1.62 Million USD | -45989.6% |
| Third Harmonic Bio, Inc. | 277.71 Million USD | -169.689% |
| ArriVent BioPharma, Inc. Common Stock | 163.09 Million USD | -359.206% |
| AN2 Therapeutics, Inc. | 138.74 Million USD | -439.811% |
| Anixa Biosciences, Inc. | 25.52 Million USD | -2834.551% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 96.705% |
| Denali Therapeutics Inc. | 1.15 Billion USD | 35.094% |
| Revelation Biosciences, Inc. | 12.21 Million USD | -6032.645% |
| Veru Inc. | 50.59 Million USD | -1380.269% |
| Corvus Pharmaceuticals, Inc. | 45.55 Million USD | -1544.142% |
| Cingulate Inc. | 3.49 Million USD | -21351.231% |
| Passage Bio, Inc. | 150.54 Million USD | -397.496% |
| Context Therapeutics Inc. | 16.06 Million USD | -4562.693% |
| Exicure, Inc. | 11.58 Million USD | -6367.668% |
| Day One Biopharmaceuticals, Inc. | 376.04 Million USD | -99.165% |
| Oramed Pharmaceuticals Inc. | 161.64 Million USD | -363.342% |
| Scinai Immunotherapeutics Ltd. | 17.47 Million USD | -4186.607% |
| Rhythm Pharmaceuticals, Inc. | 332.74 Million USD | -125.084% |
| Nuvalent, Inc. | 732.38 Million USD | -2.263% |
| ABVC BioPharma, Inc. | 14.94 Million USD | -4911.724% |
| Carisma Therapeutics, Inc. | 89.55 Million USD | -736.318% |
| Unicycive Therapeutics, Inc. | 14.19 Million USD | -5177.683% |
| OmniAb, Inc. | 401.98 Million USD | -86.314% |
| Anew Medical, Inc. | 19.45 Million USD | -3749.495% |
| Fennec Pharmaceuticals Inc. | 26.72 Million USD | -2702.292% |
| Lipocine Inc. | 23 Million USD | -3156.179% |
| Lexeo Therapeutics, Inc. Common Stock | 139.8 Million USD | -435.707% |
| Nautilus Biotechnology, Inc. | 305.56 Million USD | -145.105% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | -792.238% |
| G1 Therapeutics, Inc. | 121.54 Million USD | -516.222% |
| Bellerophon Therapeutics, Inc. | 7.93 Million USD | -9338.639% |
| Sage Therapeutics, Inc. | 882.27 Million USD | 15.111% |
| Ocugen, Inc. | 64.54 Million USD | -1060.327% |
| Mind Medicine (MindMed) Inc. | 124.54 Million USD | -501.373% |
| Q32 Bio Inc. | 306.11 Million USD | -144.662% |
| Brainstorm Cell Therapeutics Inc. | 4.2 Million USD | -17698.384% |
| Alumis Inc. Common Stock | 89.61 Million USD | -735.776% |
| Equillium, Inc. | 50.53 Million USD | -1382.201% |
| Kyverna Therapeutics, Inc. | 75.19 Million USD | -896.018% |
| Coya Therapeutics, Inc. | 41.27 Million USD | -1714.616% |
| CNS Pharmaceuticals, Inc. | 1.7 Million USD | -43934.141% |
| Galera Therapeutics, Inc. | 26.14 Million USD | -2765.063% |
| Evelo Biosciences, Inc. | 64.44 Million USD | -1062.235% |
| Comera Life Sciences Holdings, Inc. | 3.72 Million USD | -19994.803% |
| Dominari Holdings Inc. | 57.55 Million USD | -1201.22% |
| Edesa Biotech, Inc. | 8.89 Million USD | -8324.288% |
| vTv Therapeutics Inc. | 11.01 Million USD | -6697.568% |
| Bio-Techne Corporation | 2.81 Billion USD | 73.377% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | 20.079% |
| Harmony Biosciences Holdings, Inc. | 811.44 Million USD | 7.701% |
| Prelude Therapeutics Incorporated | 277.66 Million USD | -169.734% |
| Candel Therapeutics, Inc. | 41.7 Million USD | -1695.971% |
| iTeos Therapeutics, Inc. | 667.58 Million USD | -12.188% |
| Nkarta, Inc. | 378.88 Million USD | -97.674% |
| BioCardia, Inc. | 2.98 Million USD | -24973.853% |
| Iterum Therapeutics plc | 26.25 Million USD | -2752.188% |